


## (Rac)-Modipafant

## Chemical Properties

CAS No. :	122956-68-7
Formula:	C <sub>34</sub> H <sub>29</sub> ClN <sub>6</sub> O <sub>3</sub>
Molecular Weight:	605.09
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	(Rac)-Modipafant is an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia/reperfusion (I/R) in the superior mesenteric artery (SMA) of the rat.
Targets(IC50)	Anti-infection, PAFR
In vivo	In anesthetized guinea pigs, (Rac)-Modipafant(UK-74505) at 30 and 100 µg/kg intravenously inhibited the bronchoconstrictor response to aerosolized PAF without affecting blood pressure or heart rate; oral (Rac)-Modipafant(UK-74505) inhibited the increase in permeability of rat skin vessels to intradermal PAF with an ED <sub>50</sub> of 280 +/- 5 µg/kg; and in conscious dogs, complete inhibition of PAF-induced whole blood aggregation occurred in vitro for at least 14 hours following an oral dose of (Rac)-Modipafant(UK-74505)(75 µg/kg).[2]

## Solubility Information

Solubility	DMSO: 40 mg/mL (66.11 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.31 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6526 mL	8.2632 mL	16.5265 mL
5 mM	0.3305 mL	1.6526 mL	3.3053 mL
10 mM	0.1653 mL	0.8263 mL	1.6526 mL
50 mM	0.0331 mL	0.1653 mL	0.3305 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

O'Connor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. *Am J Respir Crit Care Med.* 1994 Jul;150 (1):35-40.

Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. *Agents Actions Suppl.* 1991;34:221-7.

Lefebvre JS, Marleau S, Milot V, Lévesque T, Picard S, Flamand N, Borgeat P. Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B4 and platelet-activating factor. *FASEB J.* 2010 Feb;24(2):637-47. doi: 10.1096/fj.09-135624. PubMed PMID: 19843712.

Souza DG, Fagundes CT, Sousa LP, Amaral FA, Souza RS, Souza AL, Kroon EG, Sachs D, Cunha FQ, Bukin E, Atrasheuskaya A, Ignatyev G, Teixeira MM. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. *Proc Natl Acad Sci U S A.* 2009 Aug 18;106(33):14138-43. doi: 10.1073/pnas.0906467106. PubMed PMID: 19666557; PubMed Central PMCID: PMC2729033.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481